健友股份：赖脯胰岛素预计在2027年提交申请，甘精胰岛素预计在2026年提交申请

Core Viewpoint - The company has provided updates regarding the FDA approval status of three insulin products developed in collaboration with Tonghua Dongbao, indicating that the approval timeline is subject to change and will be communicated through official announcements [1] Group 1: FDA Approval Status - The company has submitted the application for Aspart Insulin (门冬胰岛素) to the FDA and will announce the approval status promptly if granted [1] - The company anticipates submitting the application for Lispro Insulin (赖脯胰岛素) in 2027 and for Glargine Insulin (甘精胰岛素) in 2026, with these timelines being estimates [1]